Timing. Relevance. Relationships.
Fundz is the only platform that reads more than a dozen real‑time signals all day, every day, so you know about new funding, new executives and new contracts within minutes of them happening, not days or weeks later like the databases you’re used to. It then combines the signals on each company, scores every company against what you offer, and weaves in your own network, so you discover new accounts first and work existing ones better.
Each morning you get the ones worth your time right now: who to reach, why now, and who you already know there. Now it answers in Claude too: ask for today’s leads, then write the note in the same window.
Trusted by
TriGemX Bio closes a $94 million financing round co-led by The Column Group, TCGX, and Viking Global Investors to advance phase 3 trials for their migraine treatment elismetrep.
Amount Raised
$94 Million
Round Type
Venture
New YorkBiotechnologyHealth CareInvestors
Description
TriGemX Bio, a biotechnology company focused on migraine treatments, has announced the closing of a $94 million financing. The funding will support the clinical development of elismetrep, their lead program. The round was co-led by The Column Group, TCGX, and Viking Global Investors, with additional participation. This financing marks a significant step toward advancing their innovative treatment.
Fundz sees it the moment TriGemX Bio raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
TriGemX Bio raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.